Almost half of the new cases of colorectal cancer concern patients aged ≥70 years. However, very few clinical trials have specifically included older patients. As a consequence, the treatment of these patients is controversial because the balance between clinical benefits and toxicities remains uncertain. In patients without comorbidities and...
-
November 2020 (v1)Journal articleUploaded on: December 3, 2022
-
March 2006 (v1)Journal article
PURPOSE: The main treatment for resectable rectal cancer T2-T4 N0-N2 M0 is surgery. The benefit of preoperative or postoperative radiation therapy can be analyzed in terms of improvement of local control, sphincter preservation, and survival weighted against increased toxicity. METHODS: Only randomized trials can provide strong evidence of a...
Uploaded on: December 4, 2022 -
August 2019 (v1)Journal article
BACKGROUND:Response Evaluation Criteria in Solid Tumors (RECIST) are used to assess tumour shrinkage after cytotoxic chemotherapy, but may be inadequate for efficacy evaluation of anti-angiogenic therapies.AIMS:This study aimed to identify novel radiologic tumour response criteria based on early changes in tumour size and density, observed on...
Uploaded on: December 4, 2022